JP2022523105A - 免疫応答をモジュレートするenpp1阻害剤および方法 - Google Patents
免疫応答をモジュレートするenpp1阻害剤および方法 Download PDFInfo
- Publication number
- JP2022523105A JP2022523105A JP2021544572A JP2021544572A JP2022523105A JP 2022523105 A JP2022523105 A JP 2022523105A JP 2021544572 A JP2021544572 A JP 2021544572A JP 2021544572 A JP2021544572 A JP 2021544572A JP 2022523105 A JP2022523105 A JP 2022523105A
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- compound
- alkoxy
- enpp1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000812677 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 title claims abstract description 226
- 102100039306 Nucleotide pyrophosphatase Human genes 0.000 title claims abstract description 225
- 238000000034 method Methods 0.000 title claims abstract description 193
- 239000003112 inhibitor Substances 0.000 title claims abstract description 141
- 230000028993 immune response Effects 0.000 title claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 330
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 140
- 201000011510 cancer Diseases 0.000 claims abstract description 71
- 238000001959 radiotherapy Methods 0.000 claims abstract description 28
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 claims abstract description 11
- 230000005855 radiation Effects 0.000 claims abstract description 9
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 6
- 230000006378 damage Effects 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 198
- 229910052739 hydrogen Inorganic materials 0.000 claims description 124
- 239000001257 hydrogen Substances 0.000 claims description 119
- -1 phosphonate ester Chemical class 0.000 claims description 119
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 111
- 210000004027 cell Anatomy 0.000 claims description 106
- 125000003545 alkoxy group Chemical group 0.000 claims description 105
- 229910052736 halogen Inorganic materials 0.000 claims description 89
- 150000002367 halogens Chemical class 0.000 claims description 89
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 82
- 125000000623 heterocyclic group Chemical group 0.000 claims description 73
- 125000003118 aryl group Chemical group 0.000 claims description 72
- 125000002252 acyl group Chemical group 0.000 claims description 56
- 238000011282 treatment Methods 0.000 claims description 52
- 125000001072 heteroaryl group Chemical group 0.000 claims description 48
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 44
- 125000004122 cyclic group Chemical group 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 42
- 125000004432 carbon atom Chemical group C* 0.000 claims description 39
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 38
- 125000000472 sulfonyl group Chemical class *S(*)(=O)=O 0.000 claims description 37
- 239000002246 antineoplastic agent Substances 0.000 claims description 36
- 229940002612 prodrug Drugs 0.000 claims description 35
- 239000000651 prodrug Substances 0.000 claims description 35
- 229940124530 sulfonamide Drugs 0.000 claims description 32
- 150000003456 sulfonamides Chemical class 0.000 claims description 32
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 31
- 125000003342 alkenyl group Chemical group 0.000 claims description 30
- 239000000523 sample Substances 0.000 claims description 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- 229940127089 cytotoxic agent Drugs 0.000 claims description 27
- 229910052760 oxygen Inorganic materials 0.000 claims description 25
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 24
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 23
- 150000001408 amides Chemical class 0.000 claims description 23
- 229910052799 carbon Inorganic materials 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 23
- 125000003107 substituted aryl group Chemical group 0.000 claims description 22
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 21
- 229910052801 chlorine Inorganic materials 0.000 claims description 20
- 229910052731 fluorine Inorganic materials 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 125000004076 pyridyl group Chemical group 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- 239000012190 activator Substances 0.000 claims description 18
- 125000003282 alkyl amino group Chemical group 0.000 claims description 18
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 18
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 17
- 229910052794 bromium Inorganic materials 0.000 claims description 17
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 16
- 150000001412 amines Chemical class 0.000 claims description 16
- 125000000113 cyclohexyl group Chemical class [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- BUZRUIZTMOKRPB-UHFFFAOYSA-N carboxycarbamic acid Chemical compound OC(=O)NC(O)=O BUZRUIZTMOKRPB-UHFFFAOYSA-N 0.000 claims description 12
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 11
- 229910019142 PO4 Inorganic materials 0.000 claims description 11
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 11
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- 125000005024 alkenyl aryl group Chemical group 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims description 8
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 8
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 7
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 7
- 101710135378 pH 6 antigen Proteins 0.000 claims description 7
- 229910052698 phosphorus Inorganic materials 0.000 claims description 7
- 239000011574 phosphorus Substances 0.000 claims description 7
- 150000004885 piperazines Chemical class 0.000 claims description 7
- 150000003053 piperidines Chemical class 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 6
- 210000000496 pancreas Anatomy 0.000 claims description 6
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 6
- 150000003230 pyrimidines Chemical class 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 230000001919 adrenal effect Effects 0.000 claims description 5
- 125000005217 alkenylheteroaryl group Chemical group 0.000 claims description 5
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 5
- 210000003679 cervix uteri Anatomy 0.000 claims description 5
- 210000001072 colon Anatomy 0.000 claims description 5
- 230000000112 colonic effect Effects 0.000 claims description 5
- 210000003238 esophagus Anatomy 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 125000002950 monocyclic group Chemical group 0.000 claims description 5
- 210000001672 ovary Anatomy 0.000 claims description 5
- 210000002307 prostate Anatomy 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- 210000001685 thyroid gland Anatomy 0.000 claims description 5
- 210000003932 urinary bladder Anatomy 0.000 claims description 5
- 210000004291 uterus Anatomy 0.000 claims description 5
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 150000004892 pyridazines Chemical class 0.000 claims description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 3
- 239000000611 antibody drug conjugate Substances 0.000 claims description 3
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 3
- 239000003080 antimitotic agent Substances 0.000 claims description 3
- 239000013068 control sample Substances 0.000 claims description 3
- 230000001976 improved effect Effects 0.000 claims description 3
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 230000002927 anti-mitotic effect Effects 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 106
- 230000015556 catabolic process Effects 0.000 abstract description 10
- 238000006731 degradation reaction Methods 0.000 abstract description 10
- 101000995829 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Nucleotide pyrophosphatase Proteins 0.000 description 199
- XRILCFTWUCUKJR-INFSMZHSSA-N 2'-3'-cGAMP Chemical compound C([C@H]([C@H]1O)O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H]2N1C=NC2=C1NC(N)=NC2=O XRILCFTWUCUKJR-INFSMZHSSA-N 0.000 description 96
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 71
- 239000007787 solid Substances 0.000 description 71
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
- 230000002829 reductive effect Effects 0.000 description 69
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 65
- 238000002360 preparation method Methods 0.000 description 63
- 239000000243 solution Substances 0.000 description 60
- 125000005647 linker group Chemical group 0.000 description 58
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 53
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 45
- 125000001424 substituent group Chemical group 0.000 description 44
- 230000000694 effects Effects 0.000 description 40
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 39
- 125000005842 heteroatom Chemical group 0.000 description 37
- 125000004429 atom Chemical group 0.000 description 36
- 230000005865 ionizing radiation Effects 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 230000005764 inhibitory process Effects 0.000 description 31
- 229940125904 compound 1 Drugs 0.000 description 30
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 description 29
- 108030002637 Cyclic GMP-AMP synthases Proteins 0.000 description 29
- 239000003814 drug Substances 0.000 description 28
- 239000011541 reaction mixture Substances 0.000 description 27
- 235000019439 ethyl acetate Nutrition 0.000 description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 22
- 201000010099 disease Diseases 0.000 description 22
- 239000011734 sodium Substances 0.000 description 22
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- 238000004587 chromatography analysis Methods 0.000 description 21
- 125000000524 functional group Chemical group 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 19
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 19
- 125000000304 alkynyl group Chemical group 0.000 description 19
- 238000002953 preparative HPLC Methods 0.000 description 19
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 18
- 108010050904 Interferons Proteins 0.000 description 17
- 239000012267 brine Substances 0.000 description 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 17
- 125000001183 hydrocarbyl group Chemical group 0.000 description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 17
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 16
- 229910004298 SiO 2 Inorganic materials 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 150000002148 esters Chemical class 0.000 description 16
- 229920006395 saturated elastomer Polymers 0.000 description 16
- 102000014150 Interferons Human genes 0.000 description 15
- 125000000392 cycloalkenyl group Chemical group 0.000 description 15
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 14
- 229940045513 CTLA4 antagonist Drugs 0.000 description 13
- 229910052740 iodine Inorganic materials 0.000 description 13
- LLLHRNQLGUOJHP-UHFFFAOYSA-N 4-chloro-6,7-dimethoxyquinazoline Chemical compound C1=NC(Cl)=C2C=C(OC)C(OC)=CC2=N1 LLLHRNQLGUOJHP-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 210000004443 dendritic cell Anatomy 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 229940124597 therapeutic agent Drugs 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 229940079322 interferon Drugs 0.000 description 11
- 239000012299 nitrogen atmosphere Substances 0.000 description 11
- 125000000714 pyrimidinyl group Chemical group 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 150000001721 carbon Chemical group 0.000 description 10
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 10
- 125000004430 oxygen atom Chemical group O* 0.000 description 10
- 229920000728 polyester Polymers 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 9
- 239000007983 Tris buffer Substances 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- 238000002648 combination therapy Methods 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 9
- 108010067341 ectonucleotide pyrophosphatase phosphodiesterase 1 Proteins 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 9
- 235000021317 phosphate Nutrition 0.000 description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 208000032612 Glial tumor Diseases 0.000 description 8
- 206010018338 Glioma Diseases 0.000 description 8
- 229930194542 Keto Natural products 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 125000000468 ketone group Chemical group 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 230000035699 permeability Effects 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 150000003568 thioethers Chemical class 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 7
- 102000004157 Hydrolases Human genes 0.000 description 7
- 108090000604 Hydrolases Proteins 0.000 description 7
- 102100026720 Interferon beta Human genes 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 125000003710 aryl alkyl group Chemical group 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 7
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 7
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 7
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- PIINXYKJQGMIOZ-UHFFFAOYSA-N 1,2-dipyridin-2-ylethane-1,2-dione Chemical compound C=1C=CC=NC=1C(=O)C(=O)C1=CC=CC=N1 PIINXYKJQGMIOZ-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101710153168 Polyphosphate:AMP phosphotransferase Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 125000004423 acyloxy group Chemical group 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 6
- 238000011260 co-administration Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 125000004404 heteroalkyl group Chemical group 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 150000007522 mineralic acids Chemical class 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 150000007524 organic acids Chemical class 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- GVRRXASZZAKBMN-UHFFFAOYSA-N 4-chloroquinazoline Chemical compound C1=CC=C2C(Cl)=NC=NC2=C1 GVRRXASZZAKBMN-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 102100036569 Cell division cycle and apoptosis regulator protein 1 Human genes 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 5
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 5
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 5
- 150000001540 azides Chemical class 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 125000004426 substituted alkynyl group Chemical group 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 125000003396 thiol group Chemical class [H]S* 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 description 4
- 102000002281 Adenylate kinase Human genes 0.000 description 4
- 108020000543 Adenylate kinase Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- HIAKTBXSARFBHT-UHFFFAOYSA-N [1-(6,7-dimethoxyquinolin-4-yl)piperidin-4-yl]methanol Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)N1CCC(CC1)CO HIAKTBXSARFBHT-UHFFFAOYSA-N 0.000 description 4
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 4
- 125000004442 acylamino group Chemical group 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000012062 aqueous buffer Substances 0.000 description 4
- 125000004104 aryloxy group Chemical group 0.000 description 4
- 125000004181 carboxyalkyl group Chemical group 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- 229960002949 fluorouracil Drugs 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 4
- 229960005277 gemcitabine Drugs 0.000 description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 description 4
- 125000004470 heterocyclooxy group Chemical group 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 230000002601 intratumoral effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 108010093470 monomethyl auristatin E Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 4
- RQKYHDHLEMEVDR-UHFFFAOYSA-N oxo-bis(phenylmethoxy)phosphanium Chemical compound C=1C=CC=CC=1CO[P+](=O)OCC1=CC=CC=C1 RQKYHDHLEMEVDR-UHFFFAOYSA-N 0.000 description 4
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 229930195734 saturated hydrocarbon Natural products 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 125000005309 thioalkoxy group Chemical group 0.000 description 4
- 125000005296 thioaryloxy group Chemical group 0.000 description 4
- 125000005404 thioheteroaryloxy group Chemical group 0.000 description 4
- 125000004953 trihalomethyl group Chemical group 0.000 description 4
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 3
- 125000006686 (C1-C24) alkyl group Chemical class 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- MSQCQINLJMEVNJ-UHFFFAOYSA-N 1-chloroisoquinoline Chemical compound C1=CC=C2C(Cl)=NC=CC2=C1 MSQCQINLJMEVNJ-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 3
- 101000715197 Homo sapiens Cell division cycle and apoptosis regulator protein 1 Proteins 0.000 description 3
- 102000002227 Interferon Type I Human genes 0.000 description 3
- 108010014726 Interferon Type I Proteins 0.000 description 3
- 108090000467 Interferon-beta Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 102000029749 Microtubule Human genes 0.000 description 3
- 108091022875 Microtubule Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- 229910017917 NH4 Cl Inorganic materials 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 125000000033 alkoxyamino group Chemical group 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 229940100197 antimetabolite Drugs 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
- 238000009566 cancer vaccine Methods 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125833 compound 23 Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- YLFBFPXKTIQSSY-UHFFFAOYSA-N dimethoxy(oxo)phosphanium Chemical compound CO[P+](=O)OC YLFBFPXKTIQSSY-UHFFFAOYSA-N 0.000 description 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 238000005187 foaming Methods 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- 108010059074 monomethylauristatin F Proteins 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 125000005323 thioketone group Chemical group 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 2
- XRNVSPDQTPVECU-UHFFFAOYSA-N (4-bromophenyl)methanamine Chemical compound NCC1=CC=C(Br)C=C1 XRNVSPDQTPVECU-UHFFFAOYSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- SGIBOXBBPQRZDM-UHFFFAOYSA-N 1-benzylpiperidine-4-carbaldehyde Chemical compound C1CC(C=O)CCN1CC1=CC=CC=C1 SGIBOXBBPQRZDM-UHFFFAOYSA-N 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- JQOVVJMRHFEFEY-UHFFFAOYSA-N 2-(1-quinolin-4-ylpiperidin-4-yl)ethylphosphonic acid Chemical compound N1=CC=C(C2=CC=CC=C12)N1CCC(CC1)CCP(O)(O)=O JQOVVJMRHFEFEY-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
- LQQFBOQPCUBZHB-UHFFFAOYSA-N 2-[1-(6,7-dimethoxyquinolin-4-yl)piperidin-4-yl]ethanol Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)N1CCC(CC1)CCO LQQFBOQPCUBZHB-UHFFFAOYSA-N 0.000 description 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- VEDWCRGQIWOKSZ-UHFFFAOYSA-N 4-[4-(iodomethyl)piperidin-1-yl]-6,7-dimethoxyquinazoline Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N1CCC(CI)CC1 VEDWCRGQIWOKSZ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- IESYBBRQLAPZKK-UHFFFAOYSA-N COC=1C=C2C(=NC=NC2=CC=1OC)N1CCC(CC1)CCP(OC)(OC)=O Chemical compound COC=1C=C2C(=NC=NC2=CC=1OC)N1CCC(CC1)CCP(OC)(OC)=O IESYBBRQLAPZKK-UHFFFAOYSA-N 0.000 description 2
- 101710189019 Cell division cycle and apoptosis regulator protein 1 Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Chemical group 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 2
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- XGSZVHRCFIZMBN-UHFFFAOYSA-N N-[(4-bromophenyl)methyl]-6,7-dimethoxyquinazolin-4-amine hydrochloride Chemical compound COC1=C(C=C2C(=C1)C(=NC=N2)NCC3=CC=C(C=C3)Br)OC.Cl XGSZVHRCFIZMBN-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- 108010009413 Pyrophosphatases Proteins 0.000 description 2
- 102000009609 Pyrophosphatases Human genes 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000863480 Vinca Species 0.000 description 2
- 229940028652 abraxane Drugs 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000004419 alkynylene group Chemical group 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
- 108010044540 auristatin Proteins 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- XAVFZUKFLWOSOS-UHFFFAOYSA-N bis(dimethoxyphosphoryl)methane Chemical compound COP(=O)(OC)CP(=O)(OC)OC XAVFZUKFLWOSOS-UHFFFAOYSA-N 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 150000003842 bromide salts Chemical class 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 229960005501 duocarmycin Drugs 0.000 description 2
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 2
- 229930184221 duocarmycin Natural products 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- ZBRHDRZSJQAGBJ-UHFFFAOYSA-N ethyl dihydrogen phosphate Chemical compound [CH2]COP(O)(O)=O ZBRHDRZSJQAGBJ-UHFFFAOYSA-N 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000002468 fat body Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 102000046699 human CD14 Human genes 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 108010018844 interferon type III Proteins 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- QRMNENFZDDYDEF-GOSISDBHSA-N methyl (8s)-8-(bromomethyl)-2-methyl-4-(4-methylpiperazine-1-carbonyl)oxy-6-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-7,8-dihydro-3h-pyrrolo[3,2-e]indole-1-carboxylate Chemical compound C1([C@H](CBr)CN(C1=C1)C(=O)C=2NC3=C(OC)C(OC)=C(OC)C=C3C=2)=C2C(C(=O)OC)=C(C)NC2=C1OC(=O)N1CCN(C)CC1 QRMNENFZDDYDEF-GOSISDBHSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- CAAULPUQFIIOTL-UHFFFAOYSA-N methyl dihydrogen phosphate Chemical compound COP(O)(O)=O CAAULPUQFIIOTL-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 150000004712 monophosphates Chemical class 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 125000005255 oxyaminoacyl group Chemical group 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
- 150000003008 phosphonic acid esters Chemical class 0.000 description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- NLHWDDDFOOUXKD-UHFFFAOYSA-N tert-butyl 4-(3-iodopropyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CCCI)CC1 NLHWDDDFOOUXKD-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 150000007970 thio esters Chemical group 0.000 description 2
- 125000004001 thioalkyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- SVXUTKKQIPNGGL-UHFFFAOYSA-N 1-(6,7-dimethoxyquinazolin-4-yl)-N-hydroxypiperidine-4-carboxamide Chemical compound COC(C=C1C(N(CC2)CCC2C(NO)=O)=NC=NC1=C1)=C1OC SVXUTKKQIPNGGL-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- STJWVOQLJPNAQL-UHFFFAOYSA-N 1-[diethoxyphosphorylmethyl(ethoxy)phosphoryl]oxyethane Chemical compound CCOP(=O)(OCC)CP(=O)(OCC)OCC STJWVOQLJPNAQL-UHFFFAOYSA-N 0.000 description 1
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
- NDJKRLGXVKYIGQ-UHFFFAOYSA-N 1-piperidin-4-ylethanol Chemical compound CC(O)C1CCNCC1 NDJKRLGXVKYIGQ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- PMOSJSPFNDUAFY-UHFFFAOYSA-N 2-(4-bromophenyl)ethanol Chemical compound OCCC1=CC=C(Br)C=C1 PMOSJSPFNDUAFY-UHFFFAOYSA-N 0.000 description 1
- UQRVVFGDHSWXIZ-UHFFFAOYSA-N 2-[1-(3-cyano-6,7-dimethoxyquinolin-4-yl)piperidin-4-yl]ethylphosphonic acid Chemical compound C(#N)C=1C=NC2=CC(=C(C=C2C=1N1CCC(CC1)CCP(O)(O)=O)OC)OC UQRVVFGDHSWXIZ-UHFFFAOYSA-N 0.000 description 1
- XTPKECLQOCSFOI-UHFFFAOYSA-N 2-[1-(3-cyano-6-methoxyquinolin-4-yl)piperidin-4-yl]ethylphosphonic acid Chemical compound C(#N)C=1C=NC2=CC=C(C=C2C=1N1CCC(CC1)CCP(O)(O)=O)OC XTPKECLQOCSFOI-UHFFFAOYSA-N 0.000 description 1
- UAOYNRHCMHPQQR-UHFFFAOYSA-N 2-[1-(3-cyano-7-methoxyquinolin-4-yl)piperidin-4-yl]ethylphosphonic acid Chemical compound C(#N)C=1C=NC2=CC(=CC=C2C=1N1CCC(CC1)CCP(O)(O)=O)OC UAOYNRHCMHPQQR-UHFFFAOYSA-N 0.000 description 1
- UQLJJFHIDIPSII-UHFFFAOYSA-N 2-[1-(3-cyano-8-methoxyquinolin-4-yl)piperidin-4-yl]ethylboronic acid Chemical compound C(#N)C=1C=NC2=C(C=CC=C2C=1N1CCC(CC1)CCB(O)O)OC UQLJJFHIDIPSII-UHFFFAOYSA-N 0.000 description 1
- OUQXMNXTSCMWNH-UHFFFAOYSA-N 2-[1-(3-cyano-8-methoxyquinolin-4-yl)piperidin-4-yl]ethylphosphonic acid Chemical compound C(#N)C=1C=NC2=C(C=CC=C2C=1N1CCC(CC1)CCP(O)(O)=O)OC OUQXMNXTSCMWNH-UHFFFAOYSA-N 0.000 description 1
- RSLDIPVMKOODBW-UHFFFAOYSA-N 2-[1-(4-cyano-6,7-dimethoxyisoquinolin-1-yl)piperidin-4-yl]ethylphosphonic acid Chemical compound C(#N)C1=CN=C(C2=CC(=C(C=C12)OC)OC)N1CCC(CC1)CCP(O)(O)=O RSLDIPVMKOODBW-UHFFFAOYSA-N 0.000 description 1
- VDHHLOUVLSHXSH-UHFFFAOYSA-N 2-[1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl]ethanol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N1CCC(CCO)CC1 VDHHLOUVLSHXSH-UHFFFAOYSA-N 0.000 description 1
- SNLWMWQNJTVWKD-UHFFFAOYSA-N 2-[1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl]ethylphosphonic acid Chemical compound C1(OC)=C(OC)C=C2C(N3CCC(CCP(=O)(O)O)CC3)=NC=NC2=C1 SNLWMWQNJTVWKD-UHFFFAOYSA-N 0.000 description 1
- DNRXNHRWQSZDNZ-UHFFFAOYSA-N 2-[1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl]ethylurea Chemical compound COC=1C=C2C(=NC=NC2=CC=1OC)N1CCC(CC1)CCNC(=O)N DNRXNHRWQSZDNZ-UHFFFAOYSA-N 0.000 description 1
- LVYPFDQWZVCJGK-UHFFFAOYSA-N 2-[1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl]propylphosphonic acid Chemical compound COC=1C=C2C(=NC=NC2=CC=1OC)N1CCC(CC1)C(CP(O)(O)=O)C LVYPFDQWZVCJGK-UHFFFAOYSA-N 0.000 description 1
- UAYJBCRCZHDVAM-UHFFFAOYSA-N 2-[1-(6,7-dimethoxyquinolin-4-yl)piperidin-4-yl]ethylboronic acid Chemical compound COC=1C=C2C(=CC=NC2=CC=1OC)N1CCC(CC1)CCB(O)O UAYJBCRCZHDVAM-UHFFFAOYSA-N 0.000 description 1
- GOZQHMHLZDVNIY-UHFFFAOYSA-N 2-[1-(6-chloro-8-methoxyquinazolin-4-yl)piperidin-4-yl]ethylphosphonic acid Chemical compound ClC=1C=C2C(=NC=NC2=C(C=1)OC)N1CCC(CC1)CCP(O)(O)=O GOZQHMHLZDVNIY-UHFFFAOYSA-N 0.000 description 1
- WCAQSWLVEGEIFY-UHFFFAOYSA-N 2-[1-(6-fluoro-8-methoxyquinazolin-4-yl)piperidin-4-yl]ethylphosphonic acid Chemical compound FC=1C=C2C(=NC=NC2=C(C=1)OC)N1CCC(CC1)CCP(O)(O)=O WCAQSWLVEGEIFY-UHFFFAOYSA-N 0.000 description 1
- IJOILULPRNTEAN-UHFFFAOYSA-N 2-[1-(7-chloro-8-methoxyquinazolin-4-yl)piperidin-4-yl]ethylphosphonic acid Chemical compound ClC1=CC=C2C(=NC=NC2=C1OC)N1CCC(CC1)CCP(O)(O)=O IJOILULPRNTEAN-UHFFFAOYSA-N 0.000 description 1
- BEWOYZYCDRBFHX-UHFFFAOYSA-N 2-[1-(8-ethoxyquinazolin-4-yl)piperidin-4-yl]ethylphosphonic acid Chemical compound C(C)OC=1C=CC=C2C(=NC=NC=12)N1CCC(CC1)CCP(O)(O)=O BEWOYZYCDRBFHX-UHFFFAOYSA-N 0.000 description 1
- IYIDTHRXYRQJMO-UHFFFAOYSA-N 2-[1-(8-hydroxyquinazolin-4-yl)piperidin-4-yl]ethylphosphonic acid Chemical compound OC=1C=CC=C2C(=NC=NC=12)N1CCC(CC1)CCP(O)(O)=O IYIDTHRXYRQJMO-UHFFFAOYSA-N 0.000 description 1
- XBLNFSBXEDDPRK-UHFFFAOYSA-N 2-[1-(8-propan-2-yloxyquinazolin-4-yl)piperidin-4-yl]ethylphosphonic acid Chemical compound C(C)(C)OC=1C=CC=C2C(=NC=NC=12)N1CCC(CC1)CCP(O)(O)=O XBLNFSBXEDDPRK-UHFFFAOYSA-N 0.000 description 1
- NFIFYMBLRXCRNJ-UHFFFAOYSA-N 2-[4-(6,7-dimethoxyquinazolin-4-yl)piperidin-1-yl]ethylphosphonic acid Chemical compound COC=1C=C2C(=NC=NC2=CC=1OC)C1CCN(CC1)CCP(O)(O)=O NFIFYMBLRXCRNJ-UHFFFAOYSA-N 0.000 description 1
- JEORJQLNVQTPEM-UHFFFAOYSA-N 2-[4-(8-methoxyquinazolin-4-yl)phenyl]ethylphosphonic acid Chemical compound COC=1C=CC=C2C(=NC=NC=12)C1=CC=C(C=C1)CCP(O)(O)=O JEORJQLNVQTPEM-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- OFUFXTHGZWIDDB-UHFFFAOYSA-N 2-chloroquinoline Chemical compound C1=CC=CC2=NC(Cl)=CC=C21 OFUFXTHGZWIDDB-UHFFFAOYSA-N 0.000 description 1
- 125000004810 2-methylpropylene group Chemical group [H]C([H])([H])C([H])(C([H])([H])[*:2])C([H])([H])[*:1] 0.000 description 1
- VLRSADZEDXVUPG-UHFFFAOYSA-N 2-naphthalen-1-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CC2=CC=CC=C12 VLRSADZEDXVUPG-UHFFFAOYSA-N 0.000 description 1
- ZLTBINYEMMAFOM-UHFFFAOYSA-N 2-piperidin-4-ylethylboronic acid Chemical compound N1CCC(CC1)CCB(O)O ZLTBINYEMMAFOM-UHFFFAOYSA-N 0.000 description 1
- PKZMEEBWRMRMGB-UHFFFAOYSA-N 2-piperidin-4-ylethylurea Chemical compound NC(=O)NCCC1CCNCC1 PKZMEEBWRMRMGB-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 1
- HTAATWQIKVEJLS-UHFFFAOYSA-N 3-[1-(3-cyano-8-methoxyquinolin-4-yl)piperidin-4-yl]propylphosphonic acid Chemical compound C(#N)C=1C=NC2=C(C=CC=C2C=1N1CCC(CC1)CCCP(O)(O)=O)OC HTAATWQIKVEJLS-UHFFFAOYSA-N 0.000 description 1
- NLRRPLMKGZGBAH-UHFFFAOYSA-N 3-[1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl]propanoic acid Chemical compound COc1cc2ncnc(N3CCC(CCC(O)=O)CC3)c2cc1OC NLRRPLMKGZGBAH-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- AUYQMCCWFNSFGV-UHFFFAOYSA-N 3-piperidin-1-ium-4-ylpropanoate Chemical compound OC(=O)CCC1CCNCC1 AUYQMCCWFNSFGV-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- CBKDCOKSXCTDAA-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1-benzothiophene Chemical compound C1CCCC2=C1C=CS2 CBKDCOKSXCTDAA-UHFFFAOYSA-N 0.000 description 1
- ZVAYUUUQOCPZCZ-UHFFFAOYSA-N 4-(diethoxyphosphorylmethyl)aniline Chemical compound CCOP(=O)(OCC)CC1=CC=C(N)C=C1 ZVAYUUUQOCPZCZ-UHFFFAOYSA-N 0.000 description 1
- ORKZGCAUPXAZFH-UHFFFAOYSA-N 4-[4-(2-diethoxyphosphorylethyl)piperazin-1-yl]-6,7-dimethoxyquinazoline Chemical compound C(C)OP(=O)(OCC)CCN1CCN(CC1)C1=NC=NC2=CC(=C(C=C12)OC)OC ORKZGCAUPXAZFH-UHFFFAOYSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- JPRMUABPMJHKSZ-UHFFFAOYSA-N 4-[[(3-cyano-8-methoxyquinolin-4-yl)amino]methyl]-N-hydroxybenzamide Chemical compound C1=C(C2=C(C=C1)C(NCC1=CC=C(C(=O)NO)C=C1)=C(C#N)C=N2)OC JPRMUABPMJHKSZ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- KNDOFJFSHZCKGT-UHFFFAOYSA-N 4-chloroquinoline Chemical compound C1=CC=C2C(Cl)=CC=NC2=C1 KNDOFJFSHZCKGT-UHFFFAOYSA-N 0.000 description 1
- OIGQTUBEBRLSOX-UHFFFAOYSA-N 4-diethoxyphosphorylaniline Chemical compound CCOP(=O)(OCC)C1=CC=C(N)C=C1 OIGQTUBEBRLSOX-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- SMAAQNZTRQSFGG-BQYQJAHWSA-N C(=C\C1=NC2=C(C=CC=C2OC)C(=N1)N1CCC(CCP(=O)(O)O)CC1)/C1=CC=CN=C1 Chemical compound C(=C\C1=NC2=C(C=CC=C2OC)C(=N1)N1CCC(CCP(=O)(O)O)CC1)/C1=CC=CN=C1 SMAAQNZTRQSFGG-BQYQJAHWSA-N 0.000 description 1
- QSYBRUPXZOQVSH-UHFFFAOYSA-N C(C)(OC1=CC=C2C(N3CCC(CCP(=O)(O)O)CC3)=NC=NC2=C1)C Chemical compound C(C)(OC1=CC=C2C(N3CCC(CCP(=O)(O)O)CC3)=NC=NC2=C1)C QSYBRUPXZOQVSH-UHFFFAOYSA-N 0.000 description 1
- KZTTZPNSINVUQK-UHFFFAOYSA-N C(OC1=CC=C2C(N3CCC(CCP(=O)(O)O)CC3)=NC=NC2=C1)C Chemical compound C(OC1=CC=C2C(N3CCC(CCP(=O)(O)O)CC3)=NC=NC2=C1)C KZTTZPNSINVUQK-UHFFFAOYSA-N 0.000 description 1
- UOEHFUOVYSKBAQ-UHFFFAOYSA-N C1(=C(C2=C(C=C1)C(N1CCC(CC1)CCP(=O)(O)O)=NC=N2)OC)OC Chemical compound C1(=C(C2=C(C=C1)C(N1CCC(CC1)CCP(=O)(O)O)=NC=N2)OC)OC UOEHFUOVYSKBAQ-UHFFFAOYSA-N 0.000 description 1
- PENVEEYGRKZYGO-UHFFFAOYSA-N C1(N)=CC=C2C(N3CCC(CCP(=O)(O)O)CC3)=NC=NC2=C1 Chemical compound C1(N)=CC=C2C(N3CCC(CCP(=O)(O)O)CC3)=NC=NC2=C1 PENVEEYGRKZYGO-UHFFFAOYSA-N 0.000 description 1
- QCPUHCCMKQKEQH-UHFFFAOYSA-N C1(OC)=C(OC)C=C2C(C3=CC=C(CCP(=O)(O)O)C=C3)=NC=NC2=C1 Chemical compound C1(OC)=C(OC)C=C2C(C3=CC=C(CCP(=O)(O)O)C=C3)=NC=NC2=C1 QCPUHCCMKQKEQH-UHFFFAOYSA-N 0.000 description 1
- MSLWBYCGNGOQNY-UHFFFAOYSA-N C1(OC)=C(OC)C=C2C(N3CCC(CC3)CCP(=O)(O)O)=NC=CC2=C1 Chemical compound C1(OC)=C(OC)C=C2C(N3CCC(CC3)CCP(=O)(O)O)=NC=CC2=C1 MSLWBYCGNGOQNY-UHFFFAOYSA-N 0.000 description 1
- OGSAAWZBSBXTPF-UHFFFAOYSA-N C1(OC)=C(OC)C=C2C(N3CCC(CCP(=O)(O)O)CC3)=CC=NC2=C1 Chemical compound C1(OC)=C(OC)C=C2C(N3CCC(CCP(=O)(O)O)CC3)=CC=NC2=C1 OGSAAWZBSBXTPF-UHFFFAOYSA-N 0.000 description 1
- QCHHTVWKIVTHII-UHFFFAOYSA-N C1(OC)=C(OC)C=C2C(N3CCC(COP(=S)(O)O)CC3)=NC=NC2=C1 Chemical compound C1(OC)=C(OC)C=C2C(N3CCC(COP(=S)(O)O)CC3)=NC=NC2=C1 QCHHTVWKIVTHII-UHFFFAOYSA-N 0.000 description 1
- AKQPAJPKAKDQQC-UHFFFAOYSA-N C1(OC)=CC=C2C(N3CCC(CCP(=O)(O)O)CC3)=NC=NC2=C1 Chemical compound C1(OC)=CC=C2C(N3CCC(CCP(=O)(O)O)CC3)=NC=NC2=C1 AKQPAJPKAKDQQC-UHFFFAOYSA-N 0.000 description 1
- 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MAAFHWPYWJIPCN-UHFFFAOYSA-N C1=C(C2=C(C(=C1)OC)C(N1CCC(CC1)CCP(=O)(O)O)=NC=N2)OC Chemical compound C1=C(C2=C(C(=C1)OC)C(N1CCC(CC1)CCP(=O)(O)O)=NC=N2)OC MAAFHWPYWJIPCN-UHFFFAOYSA-N 0.000 description 1
- IXXUGBPAQOKGTM-UHFFFAOYSA-N C1=C(C2=C(C(N3CCC(CCP(=O)(O)O)CC3)=NC=N2)C=C1)OC Chemical compound C1=C(C2=C(C(N3CCC(CCP(=O)(O)O)CC3)=NC=N2)C=C1)OC IXXUGBPAQOKGTM-UHFFFAOYSA-N 0.000 description 1
- DEBNNSDEFAZYSR-UHFFFAOYSA-N C1=C(C2=C(C=C1OC)C(N1CCC(CCP(=O)(O)O)CC1)=NC=N2)OC Chemical compound C1=C(C2=C(C=C1OC)C(N1CCC(CCP(=O)(O)O)CC1)=NC=N2)OC DEBNNSDEFAZYSR-UHFFFAOYSA-N 0.000 description 1
- XFPWEACVENBIFZ-UHFFFAOYSA-N C1=CC(F)=C2C(N3CCC(CC3)CCP(=O)(O)O)=NC=NC2=C1OC Chemical compound C1=CC(F)=C2C(N3CCC(CC3)CCP(=O)(O)O)=NC=NC2=C1OC XFPWEACVENBIFZ-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 229940126161 DNA alkylating agent Drugs 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 230000037059 G2/M phase arrest Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241000193159 Hathewaya histolytica Species 0.000 description 1
- 101100179429 Homo sapiens IFNB1 gene Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100026688 Interferon epsilon Human genes 0.000 description 1
- 101710147309 Interferon epsilon Proteins 0.000 description 1
- 102100022469 Interferon kappa Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 1
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 241000699729 Muridae Species 0.000 description 1
- 101000776649 Mus musculus Cyclic GMP-AMP synthase Proteins 0.000 description 1
- 229910003827 NRaRb Inorganic materials 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108090000119 Nucleotidyltransferases Proteins 0.000 description 1
- 102000003832 Nucleotidyltransferases Human genes 0.000 description 1
- YBNHGBLOJHYOPT-UHFFFAOYSA-N O(C)C1=C(OC)C=C2C(N3CCC(CC(=O)NO)CC3)=NC=NC2=C1 Chemical compound O(C)C1=C(OC)C=C2C(N3CCC(CC(=O)NO)CC3)=NC=NC2=C1 YBNHGBLOJHYOPT-UHFFFAOYSA-N 0.000 description 1
- RNGNYRZBNBVKBW-UHFFFAOYSA-N O(C)C1=C(OC)C=C2C(N3CCC(CCOP(=S)(O)O)CC3)=NC=NC2=C1 Chemical compound O(C)C1=C(OC)C=C2C(N3CCC(CCOP(=S)(O)O)CC3)=NC=NC2=C1 RNGNYRZBNBVKBW-UHFFFAOYSA-N 0.000 description 1
- ILTLAOHLRJZUFA-UHFFFAOYSA-N O(C)C1=CC2=C(N3CCC(CCP(=O)(O)O)CC3)N=CN=C2C=C1 Chemical compound O(C)C1=CC2=C(N3CCC(CCP(=O)(O)O)CC3)N=CN=C2C=C1 ILTLAOHLRJZUFA-UHFFFAOYSA-N 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- KPNMQIHRHXNOHX-UHFFFAOYSA-N OC1=CC2=C(N3CCC(CCP(=O)(O)O)CC3)N=CN=C2C=C1 Chemical compound OC1=CC2=C(N3CCC(CCP(=O)(O)O)CC3)N=CN=C2C=C1 KPNMQIHRHXNOHX-UHFFFAOYSA-N 0.000 description 1
- MRGXLSCZAHCCLW-UHFFFAOYSA-N OC1=CC=C2C(N3CCC(CCP(=O)(O)O)CC3)=NC=NC2=C1 Chemical compound OC1=CC=C2C(N3CCC(CCP(=O)(O)O)CC3)=NC=NC2=C1 MRGXLSCZAHCCLW-UHFFFAOYSA-N 0.000 description 1
- 241000209094 Oryza Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 101150073131 PAP gene Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 238000001790 Welch's t-test Methods 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- CPDBXOZYUONXMF-UHFFFAOYSA-N [1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl]methanol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1N1CCC(CO)CC1 CPDBXOZYUONXMF-UHFFFAOYSA-N 0.000 description 1
- QYQOCKWOSWALFY-UHFFFAOYSA-N [1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl]methylurea Chemical compound COC1=C(C=C2C(=C1)C(=NC=N2)N3CCC(CC3)CNC(=O)N)OC QYQOCKWOSWALFY-UHFFFAOYSA-N 0.000 description 1
- AGPVXSAWSAPPCI-UHFFFAOYSA-N [1-(8-methoxyquinazolin-4-yl)piperidin-4-yl]methanol Chemical compound COC=1C=CC=C2C(=NC=NC=12)N1CCC(CC1)CO AGPVXSAWSAPPCI-UHFFFAOYSA-N 0.000 description 1
- WUBOXWSLKCBVML-UHFFFAOYSA-N [4-[[(3-cyano-8-methoxyquinolin-4-yl)amino]methyl]phenyl]boronic acid Chemical compound C(#N)C=1C=NC2=C(C=CC=C2C=1NCC1=CC=C(C=C1)B(O)O)OC WUBOXWSLKCBVML-UHFFFAOYSA-N 0.000 description 1
- BZIAHJOAINWWRJ-UHFFFAOYSA-N [4-[[(3-cyano-8-methoxyquinolin-4-yl)amino]methyl]phenyl]methylphosphonic acid Chemical compound C(#N)C=1C=NC2=C(C=CC=C2C=1NCC1=CC=C(CP(O)(O)=O)C=C1)OC BZIAHJOAINWWRJ-UHFFFAOYSA-N 0.000 description 1
- RJOVXCQSEBNNJD-UHFFFAOYSA-N [4-[[(3-cyano-8-methoxyquinolin-4-yl)amino]methyl]phenyl]phosphonic acid Chemical compound C(#N)C=1C=NC2=C(C=CC=C2C=1NCC1=CC=C(C=C1)P(O)(O)=O)OC RJOVXCQSEBNNJD-UHFFFAOYSA-N 0.000 description 1
- GVPSUAOAVQZLLN-UHFFFAOYSA-N [4-[[(6,7-dimethoxyquinazolin-4-yl)amino]methyl]phenyl]methylphosphonic acid Chemical compound COC=1C=C2C(=NC=NC2=CC=1OC)NCC1=CC=C(CP(O)(O)=O)C=C1 GVPSUAOAVQZLLN-UHFFFAOYSA-N 0.000 description 1
- MIAVIKHCFYJGKT-UHFFFAOYSA-N [4-[[(8-methoxyquinazolin-4-yl)amino]methyl]phenyl]phosphonic acid Chemical compound COC1=CC=CC2=C1N=CN=C2NCC3=CC=C(C=C3)P(=O)(O)O MIAVIKHCFYJGKT-UHFFFAOYSA-N 0.000 description 1
- OYSMALLRWJCTPC-UHFFFAOYSA-N [oxo(phenylmethoxy)-$l^{4}-phosphanyl]oxymethylbenzene Chemical compound C=1C=CC=CC=1CO[P](=O)OCC1=CC=CC=C1 OYSMALLRWJCTPC-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000006193 alkinyl group Chemical group 0.000 description 1
- 125000004171 alkoxy aryl group Chemical group 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 125000005277 alkyl imino group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940045984 antineoplastic methylhydrazine Drugs 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000005116 aryl carbamoyl group Chemical group 0.000 description 1
- 125000004467 aryl imino group Chemical group 0.000 description 1
- 125000005163 aryl sulfanyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229950004221 besilate Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 238000010888 cage effect Methods 0.000 description 1
- 230000003047 cage effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007881 chronic fibrosis Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000001360 collision-induced dissociation Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000007748 combinatorial effect Effects 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001651 cyanato group Chemical class [*]OC#N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- YOFRDVICKDKDTN-UHFFFAOYSA-N dihydroxy-[[1-(8-methoxyquinazolin-4-yl)piperidin-4-yl]methoxy]-sulfanylidene-lambda5-phosphane Chemical compound C1=C(C2=C(C=C1)C(N1CCC(COP(=S)(O)O)CC1)=NC=N2)OC YOFRDVICKDKDTN-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 229950004647 emactuzumab Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- ZTWTYVWXUKTLCP-UHFFFAOYSA-L ethenyl-dioxido-oxo-$l^{5}-phosphane Chemical compound [O-]P([O-])(=O)C=C ZTWTYVWXUKTLCP-UHFFFAOYSA-L 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- RUJPPJYDHHAEEK-UHFFFAOYSA-N ethyl piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCNCC1 RUJPPJYDHHAEEK-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 125000004997 halocarbonyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 102000050022 human STING1 Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940079826 hydrogen sulfite Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 229940126533 immune checkpoint blocker Drugs 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 150000004001 inositols Chemical class 0.000 description 1
- 108010080375 interferon kappa Proteins 0.000 description 1
- 108700027921 interferon tau Proteins 0.000 description 1
- 230000011542 interferon-beta production Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108010052322 limitin Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- RIFHJAODNHLCBH-UHFFFAOYSA-N methanethione Chemical group S=[CH] RIFHJAODNHLCBH-UHFFFAOYSA-N 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000003865 nucleic acid synthesis inhibitor Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- XNQULTQRGBXLIA-UHFFFAOYSA-O phosphonic anhydride Chemical compound O[P+](O)=O XNQULTQRGBXLIA-UHFFFAOYSA-O 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- XBXHCBLBYQEYTI-UHFFFAOYSA-N piperidin-4-ylmethanol Chemical compound OCC1CCNCC1 XBXHCBLBYQEYTI-UHFFFAOYSA-N 0.000 description 1
- DTZYYZWYSRPUGM-UHFFFAOYSA-N piperidin-4-ylmethylurea Chemical compound NC(=O)NCC1CCNCC1 DTZYYZWYSRPUGM-UHFFFAOYSA-N 0.000 description 1
- 125000004585 polycyclic heterocycle group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 125000006239 protecting group Chemical class 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012070 reactive reagent Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Substances [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- IUIVSFUZFWYZHL-DHZHZOJOSA-N tert-butyl 4-[(e)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)ethenyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1\C=C\B1OC(C)(C)C(C)(C)O1 IUIVSFUZFWYZHL-DHZHZOJOSA-N 0.000 description 1
- INUWDZDWSJJFSQ-UHFFFAOYSA-N tert-butyl 4-ethynylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C#C)CC1 INUWDZDWSJJFSQ-UHFFFAOYSA-N 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- 125000005063 tetradecenyl group Chemical group C(=CCCCCCCCCCCCC)* 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 150000003580 thiophosphoric acid esters Chemical class 0.000 description 1
- 239000003734 thymidylate synthase inhibitor Substances 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Substances C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
- 239000003744 tubulin modulator Substances 0.000 description 1
- 230000005851 tumor immunogenicity Effects 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 1
- 229960001183 venetoclax Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/60—Quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Abstract
Description
政府の権利
環状グアノシン一リン酸-アデノシン一リン酸(cGAMP)は、重要な抗がん自然免疫経路である、インターフェロン遺伝子の刺激因子(STING)の経路を活性化する。cGAS-cGAMP-STING経路は、微生物感染、またはがんおよび自然免疫障害を含めた病態生理学的状態のどちらか一方に起因して、細胞質DNAの存在下で活性化を受ける。環状GMP-AMPシンターゼ(cGAS)は、ヌクレオチジルトランスフェラーゼファミリーに属し、サイトゾルdsDNAに結合すると活性化されて、シグナル伝達分子(2’-5’、3’-5’)環状GMP-AMP(または2’,3’-cGAMP、または環状グアノシン一リン酸-アデノシン一リン酸であるcGAMP)を産生する万能DNAセンサーである。2’,3’-cGAMPは、微生物感染の間の第2のメッセンジャーとして作用すると、STINGに結合してこれを活性化し、免疫応答の引き金となるI型インターフェロン(IFN)および他の共刺激性分子の産生をもたらす。STING経路は、感染症におけるその役割の他に、がん免疫療法および自己免疫疾患に対する標的として浮上している。
本開示の実施形態をさらに記載する前に、本開示は、記載されている特定の実施形態に限定されず、したがって、当然ながら様々になり得ることを理解すべきである。本開示の範囲は添付の特許請求の範囲によってしか限定されないので、本明細書において使用される用語は、特定の実施形態を記載することを目的としているに過ぎず、限定的であることを意図するものではないことをやはり理解すべきである。
詳細な説明
ENPP1阻害剤化合物
X1は、親水性頭部基(例えば、本明細書に記載されている)であり、
Aは、アリール、置換アリール、ヘテロアリール、置換ヘテロアリール、シクロアルキル、置換シクロアルキル、複素環および置換複素環から選択される環系であり、
L1およびL2は、独立して、共有結合またはリンカーであり、
Z3は、存在しないか、またはNR22、OおよびSから選択され、
Z2は、CR12またはNであり、
Z1は、CR11またはNであり、
R1は、H、アルキル、置換アルキル、アルケニル、置換アルケニル、アルキルアリール、置換アルキルアリール、アルキルヘテロアリール、置換アルキルヘテロアリール、アルケニルアリール(例えば、エテニルアリール)、置換アルケニルアリール、アルケニルヘテロアリール(例えば、エテニルヘテロアリール)、置換アルケニルヘテロアリール、アリール、置換アリール、ヘテロアリール、置換ヘテロアリール、複素環および置換複素環から選択され、
R11およびR12は、H、シアノ、トリフルオロメチル、ハロゲン、アルキルおよび置換アルキルから独立して選択され、
R22は、H、アルキルおよび置換アルキルから選択され、
R2~R5は、H、OH、アルキル、置換アルキル、アルケニル、置換アルケニル、アルコキシ、置換アルコキシ、-OCF3、ハロゲン、シアノ、アミン、置換アミン、アミド、複素環および置換複素環から独立して選択されるか、またはR2とR3、R3とR4もしくはR4とR5は、それらが結合している炭素原子と一緒になって、複素環、置換複素環、シクロアルキル、置換シクロアルキル、アリールおよび置換アリールから選択される縮合環(例えば、5員または6員の単環式環)をもたらす)
またはそのプロドラッグ、薬学的に許容される塩もしくは溶媒和物である。
によって記載することができる。
R31~R34はそれぞれ、H、ハロゲン、アルキルおよび置換アルキルから独立して選択されるか、またはR31とR32もしくはR33とR34は、環式連結しており、それらが結合している炭素原子と一緒になって、シクロアルキル、置換シクロアルキル、ヘテロシクリルまたは置換ヘテロシクリル環をもたらし、
nおよびmは、それぞれ独立して、0~6の整数(例えば、0~3)である)
のものである。
Z41は、-NR22C(=O)-であり、
R31~R34はそれぞれ、H、ハロゲン、アルキルおよび置換アルキルから独立して選択されるか、またはR31とR32もしくはR33とR34は、環式連結しており、それらが結合している炭素原子と一緒になって、シクロアルキル、置換シクロアルキル、ヘテロシクリルまたは置換ヘテロシクリル環をもたらし、
nおよびmは、それぞれ独立して、0~6の整数(例えば、0~3)である)
のものである。
R6はそれぞれ、水素、アルキル、置換アルキル、ヒドロキシ、アルコキシ、置換アルコキシ、トリフルオロメチル、ハロゲン、アシル、置換アシル、カルボキシ、カルボキシアミド、置換カルボキシアミド、スルホニル、置換スルホニル、スルホンアミドおよび置換スルホンアミドから選択され、
pは、0~4の整数である)
によって記載される。
Z5は、NおよびCR6から選択され、
R6はそれぞれ、水素、アルキル、置換アルキル、ヒドロキシ、アルコキシ、置換アルコキシ、トリフルオロメチル、ハロゲン、アシル、置換アシル、カルボキシ、カルボキシアミド、置換カルボキシアミド、スルホニル、置換スルホニル、スルホンアミドおよび置換スルホンアミドから選択され、
qは、0~2の整数である)
によって記載される。
Z5は、NおよびCR6から選択され、
R6はそれぞれ、水素、アルキル、置換アルキル、ヒドロキシ、アルコキシ、置換アルコキシ、トリフルオロメチル、ハロゲン、アシル、置換アシル、カルボキシ、カルボキシアミド、置換カルボキシアミド、スルホニル、置換スルホニル、スルホンアミドおよび置換スルホンアミドから選択され、
qは、0~2の整数である)
によって記載される。
Z5は、Nであり、
R6はそれぞれ、水素、アルキル、置換アルキル、ヒドロキシ、アルコキシ、置換アルコキシ、トリフルオロメチル、ハロゲン、アシル、置換アシル、カルボキシ、カルボキシアミド、置換カルボキシアミド、スルホニル、置換スルホニル、スルホンアミドおよび置換スルホンアミドから選択され、
qは、0~2の整数である)
によって記載される。
Z31は、NR22、OおよびSから選択され、
Z41は、-NR22C(=O)-であり、
Z11およびZ21は、NおよびC(CN)から独立して選択され、
R31~R34はそれぞれ、H、ハロゲン、アルキルおよび置換アルキルから独立して選択されるか、またはR31とR32もしくはR33とR34は、環式連結しており、それらが結合している炭素原子と一緒になって、シクロアルキル、置換シクロアルキル、ヘテロシクリルまたは置換ヘテロシクリル環をもたらし、
R6はそれぞれ、H、アルキル、置換アルキル、ヒドロキシ、アルコキシ、置換アルコキシ、トリフルオロメチルおよびハロゲンから独立して選択され、
pは、0~4の整数であり、
nおよびmは、それぞれ独立して、0~6の整数(例えば、0~3)である)
のものである。
R41~R44は、水素、アルキル、置換アルキル、ヒドロキシ、アルコキシ、置換アルコキシ、トリフルオロメチル、ハロゲン、アシル、置換アシル、カルボキシ、カルボキシアミド、置換カルボキシアミド、スルホニル、置換スルホニル、スルホンアミドおよび置換スルホンアミドから独立して選択される)
のものである。
Z5は、NおよびCR6から選択され、
R6はそれぞれ、水素、アルキル、置換アルキル、ヒドロキシ、アルコキシ、置換アルコキシ、トリフルオロメチル、ハロゲン、アシル、置換アシル、カルボキシ、カルボキシアミド、置換カルボキシアミド、スルホニル、置換スルホニル、スルホンアミドおよび置換スルホンアミドから選択され、
pは、0~4の整数であり、
qは、0~2の整数である)
により記載される(例えば、本明細書に記載されている)。
Z5はそれぞれ、NおよびCR16から独立して選択され、
R16はそれぞれ、水素、アルキル、置換アルキル、ヒドロキシ、アルコキシ、置換アルコキシ、トリフルオロメチル、ハロゲン、アシル、置換アシル、カルボキシ、カルボキシアミド、置換カルボキシアミド、スルホニル、置換スルホニル、スルホンアミドおよび置換スルホンアミドから独立して選択され、
rは、0~8の整数である)
によって記載される。
Z5はそれぞれ、NおよびCR16から独立して選択され、
R16はそれぞれ、水素、アルキル、置換アルキル、ヒドロキシ、アルコキシ、置換アルコキシ、トリフルオロメチル、ハロゲン、アシル、置換アシル、カルボキシ、カルボキシアミド、置換カルボキシアミド、スルホニル、置換スルホニル、スルホンアミドおよび置換スルホンアミドから独立して選択され、
rは、0~8の整数である)
のものである。
R35およびR36はそれぞれ、H、ハロゲン、アルキルおよび置換アルキルから独立して選択されるか、またはR35およびR36は、環式連結しており、それらが結合している炭素原子と一緒になって、シクロアルキル、置換シクロアルキル、ヘテロシクリルまたは置換ヘテロシクリル環をもたらし、
sは、0~6の整数(例えば、0~3)である)
のものである。
sは、0~3であり、
R21は、C(1~6)アルキルまたは置換C(1~6)アルキルであり、
R3およびR4は、ClおよびFから選択される)
のものである。
Z6は、存在しないか、またはOおよびCH2から選択され、
Z7およびZ9は、OおよびNR10からそれぞれ独立して選択され、R10は、H、アルキルまたは置換アルキルであり、
Z8は、OおよびSから選択され、
R8およびR9は、H、アルキル、置換アルキル、アルケニル、置換アルケニル、アリール、置換アリール、ヘテロアリール、置換ヘテロアリール、アシル、置換アシル、非芳香族複素環、置換非芳香族複素環、シクロアルキル、置換シクロアルキルおよびプロ部分からそれぞれ独立して選択される)
のものである。
R10およびR11は、H、アルキル、置換アルキル、アルコキシ、置換アルコキシ、アリール、置換アリール、ヘテロアリール、置換ヘテロアリール、アシル、置換アシル、カルボキシル、置換カルボキシルおよびプロ部分(例えば、本明細書に記載されている)からそれぞれ独立して選択される)
から選択される。
R81およびR91は、H、アルキル、置換アルキル、アルケニル、置換アルケニル、アルコキシ、置換アルコキシ、アリール、置換アリール、アシル基、エステル、アミド、複素環、置換複素環 シクロアルキルおよび置換シクロアルキルからそれぞれ独立して選択されるか、またはR81とR91は、それらが結合している原子と一緒になって、複素環および置換複素環から選択される基を形成する)
のものである。
R92は、H、アルキル、置換アルキル、アルケニル、置換アルケニル、アルコキシ、置換アルコキシ、アリール、置換アリール、アシル基、エステル、アミド、複素環、置換複素環 シクロアルキルおよび置換シクロアルキルから選択される)
のものである。
ENPP1を阻害する方法
処置の方法
併用療法
cGAMP誘導化学療法剤との組合せ
併用放射線療法
有用性
医薬組成物
化合物の合成
例示的な合成スキーム 化合物1
LC-MS:m/z=410.25[M+H]+
1H NMR (500 MHz, CDCl3) δ 8.65 (s, 1H), 7.23 (s, 1H), 7.09 (s, 1H), 4.19 (dq, J = 14.0,2.9, 2.4 Hz, 2H), 4.02 (s, 3H), 3.99 (s, 3H), 3.77 (s, 3H), 3.75 (s, 3H), 3.05 (td, J = 12.8,2.3 Hz, 2H), 1.93 - 1.77 (m, 4H), 1.67 (ddd, J = 14.1, 9.5, 5.9 Hz, 3H), 1.46 (qd, J =12.2, 3.7 Hz, 2H).
LC-MS:m/z=381.8[M+H]+
1H NMR (500 MHz, DMSO-d6) δ 8.77 (s, 1H), 7.34 (s, 1H), 7.23 (s, 1H), 4.71 (d, J =13.1 Hz, 2H), 3.99 (s, 3H), 3.97 (s, 3H), 3.48 (t, J = 12.7 Hz, 2H), 3.18 (s, 1H), 1.97-1.90 (m, 2H), 1.62-1.43 (m, 4H), 1.40-1.27 (m, 2H).
化合物5(表1)の合成
化合物6(表1)の合成
1-(6,7-ジメトキシキナゾリン-4-イル)-N-ヒドロキシピペリジン-4-カルボキサミド9(表3a中)の調製
(2-(1-(7-メトキシキナゾリン-4-イル)ピペリジン-4-イル)エチル)ホスホン酸27の調製
(2-(1-(7-アミノキナゾリン-4-イル)ピペリジン-4-イル)エチル)ホスホン酸30の調製
(2-(1-(8-イソプロポキシキナゾリン-4-イル)ピペリジン-4-イル)エチル)ホスホン酸34(表3a中)の調製
(2-(1-(8-ヒドロキシキナゾリン-4-イル)ピペリジン-4-イル)エチル)ホスホン酸36(表3a中)の調製
(2-(1-(5,8-ジメトキシキナゾリン-4-イル)ピペリジン-4-イル)エチル)ホスホン酸36の調製
(2-(1-(7,8-ジヒドロ-[1,4]ジオキシノ[2,3-g]キナゾリン-4-イル)ピペリジン-4-イル)エチル)ホスホン酸39(表3a中)の調製
(2-(1-(5-フルオロ-8-メトキシキナゾリン-4-イル)ピペリジン-4-イル)エチル)ホスホン酸40(表3a中)の調製
(E)-(2-(1-(8-メトキシ-2-(2-(ピリジン-3-イル)ビニル)キナゾリン-4-イル)ピペリジン-4-イル)エチル)ホスホン酸45の調製
(2-(1-(6,7-ジメトキシイソキノリン-1-イル)ピペリジン-4-イル)エチル)ホスホン酸51の調製
(((1-(8-メトキシキナゾリン-4-イル)ピペリジン-4-イル)オキシ)メチル)ホスホン酸54(表3a中)の調製
(4-(((3-シアノ-8-メトキシキノリン-4-イル)アミノ)メチル)フェニル)ホスホン酸57(表1中で52とも称される)の調製
化合物活性の評価
細胞外ENPP1、および細胞外ENPP1の阻害の実証
ENPP1の阻害により、一次CD14+単球のcGAMP活性化が向上する
ENPP1阻害は、電離放射線(IR)処置と相乗作用し、腫瘍関連樹状細胞を増大させる。
ENPP1阻害は、IR処置および抗CTLA-4と相乗作用し、抗腫瘍作用を発揮する
(実施例7)
2’3’-cGAMPは、がん細胞により生成され、ENPP1によって調節される免疫伝達物質である
導入部
物質および方法
結果
cGAMPが細胞外に存在するという仮説を試験するため、本発明者らは、最初に、複雑な混合物からcGAMPを検出する液体クロマトグラフィー-タンデム型質量分析法(LC-MS/MS)法を開発した。本発明者らは、2つの同位体標識されているcGAMP標準(図1のパネルA)を使用して、基底細胞培養培地および血清含有培地の両方において、cGAMP濃度を0.5nMの低濃度まで定量することができ、本発明者らは、同じ実験において、細胞抽出物から細胞内cGAMP濃度を定量することができる(図1のパネルB、ならびに図8のパネルAおよびB)。本発明者らは、cGASもSTINGも発現しない293T細胞の使用を選択する。本発明者らは、マウスcGASを安定的に発現し、CRISPRを使用してENPP1をノックアウトすることによって、293T cGAS ENPP1low細胞系を生成した(図8のパネルC)。次に、本発明者らは、単一クローンを単離し、293T cGAS ENPP1-/-細胞系を生成した(図8のパネルC)。血清は、ENPP1のタンパク質分解により切断された可溶形態を含有するので、本発明者らは血清不含培地も使用した。本発明者らは、このENPP1不含細胞培養物系を使用して、いかなる刺激もなしに、293T cGAS ENPP1-/-細胞中で一定の低いマイクロモル濃度の基底細胞内cGAMP濃度を検出した(図1のパネルC)。誤ったDNA分離の結果として、がん細胞においてサイトゾルdsDNAが多量に存在するので、これは驚くべきことではない(例えば、Mackenzie, K. J. et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature 548, 461-465 (2017); Harding, S. M. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature 548, 466-470 (2017);およびBakhoum, S. F. et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature 553, 467-472 (2018)を参照されたい)。本発明者らは、新しい培地を細胞に補充した後、30時間後に、細胞外cGAMP濃度の100nMまでの直線的な向上を測定した(図1のパネルD)。30時間時に、細胞の外側のcGAMP分子の数は、内側の数に等しかった(図1のパネルE)。本発明者らは、細胞外ラクトースデヒドロゲネート(dehydrogenate)(LDH)活性に基づいて無視できる程度の細胞死の量を検出し、培地中のcGAMPは生細胞によって排出されることを示唆している(図1のパネルE)。本発明者らは、排出速度(vexport)が、220分子 細胞-1s-1であると計算した(図1のパネルF)。最後に、培地中のcGAMPは、10kDaのフィルターを何ら保持されることなく通過することができ、これは、細胞外ベシクルおよびタンパク質を保持しているはずであり、cGAMPは、自由に可溶性の分子として排出されることを示唆している(図1のパネルH)。
a、QS1の構造、およびpH7.5における、基質として32P-cGAMPを用いる精製マウスENPP1に対するその阻害活性(化合物1との比較)(QS1 Ki,app=6.4±3.2μM)。平均値±標準誤差(n=2独立実験)。b、QS1の存在下または非存在下で、空のベクターまたはヒトENPP1を含有するベクターをトランスフェクトした293T cGAS ENPP1-/-細胞に関する細胞内、細胞外および全cGAMP。平均値±標準誤差(n=2)。*P<0.05。**P<0.01(一元配置ANOVA)。
Claims (90)
- 式(I)の化合物:
X1は、親水性頭部基(例えば、亜鉛イオンと結合することが可能なリン含有基)であり、
Aは、アリール、置換アリール、ヘテロアリール、置換ヘテロアリール、シクロアルキル、置換シクロアルキル、複素環および置換複素環から選択される環系であり、
L1およびL2は、独立して、共有結合またはリンカーであり、
Z3は、存在しないか、またはNR22、OおよびSから選択され、
Z2は、CR12またはNであり、
Z1は、CR11またはNであり、
R1は、H、アルキル、置換アルキル、アルケニル、置換アルケニル、アルキルアリール、置換アルキルアリール、アルキルヘテロアリール、置換アルキルヘテロアリール、アルケニルアリール(例えば、エテニルアリール)、置換アルケニルアリール、アルケニルヘテロアリール(例えば、エテニルヘテロアリール)、置換アルケニルヘテロアリール、アリール、置換アリール、ヘテロアリール、置換ヘテロアリール、複素環および置換複素環から選択され、
R11およびR12は、H、シアノ、トリフルオロメチル、ハロゲン、アルキルおよび置換アルキルから独立して選択され、
R22は、H、アルキルおよび置換アルキルから選択され、
R2~R5は、H、OH、アルキル、置換アルキル、アルケニル、置換アルケニル、アルコキシ、置換アルコキシ、-OCF3、ハロゲン、シアノ、アミン、置換アミン、アミド、複素環および置換複素環から独立して選択されるか、またはR2とR3、R3とR4もしくはR4とR5は、それらが結合している炭素原子と一緒になって、複素環、置換複素環、シクロアルキル、置換シクロアルキル、アリールおよび置換アリールから選択される縮合環(例えば、5員または6員の単環式環)をもたらす]
またはそのプロドラッグ、薬学的に許容される塩もしくは溶媒和物。 - Z31が、NR22であり、
R22が、H、C(1~6)アルキルおよび置換C(1~6)アルキルから選択される、
請求項2に記載の化合物。 - n+mが0~3(例えば、0、1、2または3)である、請求項4に記載の化合物。
- 前記環系Aが、フェニル、置換フェニル、ピリジル、置換ピリジル、ピリミジン、置換ピリミジン、ピペリジン、置換ピペリジン、ピペラジン、置換ピペラジン、ピリダジン、置換ピリダジン、シクロヘキシルおよび置換シクロヘキシルから選択される、請求項1から5のいずれか一項に記載の化合物。
- R1が、H、アルキルアリール、置換アルキルアリール、アルキルヘテロアリール、置換アルキルヘテロアリール、アルケニルアリール(例えば、エテニルアリール)、置換アルケニルアリール、アルケニルヘテロアリール(例えば、エテニルヘテロアリール)、置換アルケニルヘテロアリール、アリール、置換アリール、ヘテロアリールおよび置換ヘテロアリールから選択される、請求項1から10のいずれか一項に記載の化合物。
- R1が、H、エテニルアリール、置換エテニルアリール、エテニルヘテロアリールおよび置換エテニルヘテロアリールから選択される、請求項11に記載の化合物。
- R2~R5が、H、OH、アルキル、置換アルキル、アルコキシ、置換アルコキシ、-OCF3、ハロゲン、シアノ、アミン、置換アミン、アミド、複素環および置換複素環から独立して選択される、請求項1から13のいずれか一項に記載の化合物。
- R2~R5が、H、OH、C(1~6)アルコキシ、-OCF3、C(1~6)アルキルアミノ、ジ-C(1~6)アルキルアミノ、F、Cl、BrおよびCNから独立して選択される、請求項14に記載の化合物。
- R3およびR4が、独立して、アルコキシであり、
R2およびR5が、水素である、
請求項14に記載の化合物。 - R3が、アルコキシであり、
R2、R4およびR5が、水素である、
請求項14に記載の化合物。 - R4が、アルコキシであり、
R2、R3およびR5が、水素である、
請求項14に記載の化合物。 - R2、R3およびR4が、Hであり、
R5が、アルコキシである、
請求項14に記載の化合物。 - nが0であり、mが1である、請求項4から19のいずれか一項に記載の化合物。
- nが1であり、mが0である、請求項4から19のいずれか一項に記載の化合物。
- nおよびmがどちらも1である、請求項4から19のいずれか一項に記載の化合物。
- nおよびmがどちらも0である、請求項4から19のいずれか一項に記載の化合物。
- 前記環系Aが、フェニル、置換フェニル、ピリジル、置換ピリジル、ピリミジン、置換ピリミジン、ピペリジン、置換ピペリジン、ピペラジン、置換ピペラジン、ピリダジン、置換ピリダジン、シクロヘキシルおよび置換シクロヘキシルから選択される、請求項24に記載の化合物。
- Z5がNである、請求項27に記載の化合物。
- R2~R5が、H、OH、アルキル、置換アルキル、アルコキシ、置換アルコキシ、-OCF3、ハロゲン、シアノ、アミン、置換アミン、アミド、複素環および置換複素環から独立して選択される、請求項24から30のいずれか一項に記載の化合物。
- R2~R5が、H、OH、C(1~6)アルコキシ、-OCF3、C(1~6)アルキルアミノ、ジ-C(1~6)アルキルアミノ、F、Cl、BrおよびCNから独立して選択される、請求項31に記載の化合物。
- R3およびR4が、独立して、アルコキシであり、
R2およびR5が、水素である、
請求項31に記載の化合物。 - R3が、アルコキシであり、
R2、R4およびR5が、水素である、
請求項31に記載の化合物。 - R4が、アルコキシであり、
R2、R3およびR5が、水素である、
請求項31に記載の化合物。 - R2、R3およびR4が、Hであり、
R5が、アルコキシである、
請求項31に記載の化合物。 - sが1である、請求項29から36のいずれか一項に記載の化合物。
- sが2である、請求項29から36のいずれか一項に記載の化合物。
- sが3である、請求項29から36のいずれか一項に記載の化合物。
- X1が、亜鉛イオンに結合することが可能な荷電リン含有基をマスクするプロ部分を含む、請求項1から39のいずれか一項に記載の化合物。
- X1が、ホスホン酸、ホスホネート、ホスホン酸エステル、ホスフェート、リン酸エステル、チオホスフェート、チオリン酸エステル、ホスホロアミデートおよびチオホスホロアミデートから選択される、請求項41から40のいずれか一項に記載の化合物。
- ENPP1機能を阻害する手段、および
薬学的に許容される賦形剤
を含む、医薬組成物。 - ENPP1機能を阻害する前記手段が、請求項1から46のいずれか一項に記載のENPP1阻害剤である、請求項47に記載の医薬組成物。
- がんの処置に使用するための医薬組成物であって、
請求項1から46のいずれか一項に記載のENPP1阻害剤、および
薬学的に許容される賦形剤
を含む、医薬組成物。 - ENPP1を阻害する方法であって、
ENPP1を含む試料に、請求項1から46のいずれか一項に記載のENPP1阻害剤を接触させて、前記ENPP1のcGAMP加水分解活性を阻害するステップ
を含む、方法。 - 前記ENPP1阻害剤が、細胞非透過性である、請求項50に記載の方法。
- 前記ENPP1阻害剤が、細胞透過性である、請求項50に記載の方法。
- 前記試料が細胞試料である、請求項50から52のいずれか一項に記載の方法。
- 前記試料がcGAMPを含む、請求項53に記載の方法。
- cGAMPレベルが、前記細胞試料中で向上している(例えば、前記ENPP1阻害剤と接触していない対照試料との比較)、請求項54に記載の方法。
- がんを処置する方法であって、
がんを有する被験体に、治療有効量の請求項1から46のいずれか一項に記載のENPP1阻害剤を投与して、前記被験体のがんを処置するステップ
を含む、方法。 - がんを処置する方法であって、
がんを有する被験体に、治療有効量のENPP1機能を阻害する手段を投与して、前記被験体のがんを処置するステップ
を含む、方法。 - 前記がんが固形腫瘍がんである、請求項56または57に記載の方法。
- 前記がんが、副腎、肝臓、腎臓、膀胱、乳房、結腸、胃、卵巣、子宮頸部、子宮、食道、結腸直腸、前立腺、膵臓、肺(小細胞と非小細胞の両方)、甲状腺、癌腫、肉腫、神経膠芽腫、黒色腫および様々な頭頸部腫瘍から選択される、請求項56から58のいずれか一項に記載の方法。
- 前記がんが乳がんである、請求項59に記載の方法。
- 前記がんがリンパ腫である、請求項56または57に記載の方法。
- 前記がんが神経膠芽腫である、請求項59に記載の方法。
- 有効量の1種または複数種の追加の活性剤を前記被験体に投与するステップをさらに含む、請求項56から62のいずれか一項に記載の方法。
- 前記1種または複数種の追加の活性剤が、化学療法剤または免疫治療剤である、請求項63に記載の方法。
- 前記1つまたは複数の追加の活性剤が、低分子、抗体、抗体断片、抗体-薬物コンジュゲート、アプタマーまたはタンパク質である、請求項63または64に記載の方法。
- 前記1つまたは複数の追加の活性剤が、チェックポイント阻害剤を含む、請求項63から65のいずれか一項に記載の方法。
- 前記チェックポイント阻害剤が、細胞傷害性Tリンパ球関連抗原4(CTLA-4)阻害剤、プログラム死1(PD-1)阻害剤およびPD-L1阻害剤から選択される、請求項66に記載の方法。
- 前記1つまたは複数の追加の活性剤が、化学療法剤を含む、請求項63から65のいずれか一項に記載の方法。
- 前記化学療法剤が、cGAMP誘導化学療法剤である、請求項68に記載の方法。
- cGAMP誘導化学療法剤が、前記被験体におけるcGAMPの生成を誘導するのに有効な量で投与される抗有糸分裂剤または抗腫瘍剤である、請求項69に記載の方法。
- 前記被験体に放射線療法を投与するステップをさらに含む、請求項56から70のいずれか一項に記載の方法。
- 前記阻害剤が放射線療法の前に前記被験体に投与される、請求項71に記載の方法。
- 前記阻害剤が、放射線療法への前記被験体の曝露後に投与される、請求項71に記載の方法。
- 前記放射線療法が前記被験体におけるcGAMPの生成を誘導する、請求項72または73に記載の方法。
- 前記放射線療法が、前記被験体への放射線損傷を軽減するのに有効な程度の投与量および/または頻度で投与される、請求項71から74のいずれか一項に記載の方法。
- 前記ENPP1阻害剤が細胞非透過性である、請求項56から75のいずれか一項に記載の方法。
- 前記ENPP1阻害剤が細胞透過性である、請求項56から75のいずれか一項に記載の方法。
- がんを処置する際に使用するための、請求項1から46のいずれか一項に記載のENPP1阻害剤。
- がんを処置するための医薬の製造における、請求項1から46のいずれか一項に記載のENPP1阻害剤の使用。
- 被験体における、免疫応答をモジュレートする方法であって、
治療有効量の請求項1から46のいずれか一項に記載のENPP1阻害剤を被験体に投与して、前記被験体の炎症状態を処置するステップ
を含む、方法。 - 被験体における、免疫応答をモジュレートする方法であって、
被験体に治療有効量のENPP1機能を阻害するための手段を投与して、前記被験体の炎症状態を処置するステップ
を含む、方法。 - 前記環系Aが、フェニル、置換フェニル、ピリジル、置換ピリジル、ピリミジン、置換ピリミジン、ピペリジン、置換ピペリジン、ピペラジン、置換ピペラジン、ピリダジン、置換ピリダジン、シクロヘキシルおよび置換シクロヘキシルから選択される、請求項82に記載の化合物。
- Z5がNである、請求項85に記載の化合物。
- R2~R5が、H、OH、アルキル、置換アルキル、アルコキシ、置換アルコキシ、-OCF3、ハロゲン、シアノ、アミン、置換アミン、アミド、複素環および置換複素環から独立して選択される、請求項82から87のいずれか一項に記載の化合物。
- R2~R5が、H、OH、C(1~6)アルコキシ、-OCF3、C(1~6)アルキルアミノ、ジ-C(1~6)アルキルアミノ、F、Cl、BrおよびCNから独立して選択される、請求項89に記載の化合物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962800283P | 2019-02-01 | 2019-02-01 | |
US62/800,283 | 2019-02-01 | ||
US201962814745P | 2019-03-06 | 2019-03-06 | |
US62/814,745 | 2019-03-06 | ||
PCT/US2020/015968 WO2020160333A1 (en) | 2019-02-01 | 2020-01-30 | Enpp1 inhibitors and methods of modulating immune response |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022523105A true JP2022523105A (ja) | 2022-04-21 |
JPWO2020160333A5 JPWO2020160333A5 (ja) | 2022-12-28 |
Family
ID=71842335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021544572A Pending JP2022523105A (ja) | 2019-02-01 | 2020-01-30 | 免疫応答をモジュレートするenpp1阻害剤および方法 |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220289775A1 (ja) |
EP (1) | EP3917536A4 (ja) |
JP (1) | JP2022523105A (ja) |
KR (1) | KR20210124265A (ja) |
CN (1) | CN113677350A (ja) |
AU (1) | AU2020214628A1 (ja) |
BR (1) | BR112021015098A2 (ja) |
CA (1) | CA3128044A1 (ja) |
CL (1) | CL2021002002A1 (ja) |
CO (1) | CO2021010186A2 (ja) |
IL (1) | IL284961A (ja) |
MA (1) | MA54879A (ja) |
MX (1) | MX2021009269A (ja) |
PE (1) | PE20212306A1 (ja) |
SG (1) | SG11202108288YA (ja) |
TW (1) | TW202214571A (ja) |
WO (1) | WO2020160333A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL302338A (en) | 2017-09-08 | 2023-06-01 | Univ Leland Stanford Junior | ENPP1 inhibitors and their use for cancer treatment |
WO2020140001A1 (en) * | 2018-12-28 | 2020-07-02 | Riboscience Llc | Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
CN115151253A (zh) * | 2019-09-23 | 2022-10-04 | 南京征祥医药有限公司 | 磷酸二酯酶抑制剂及用途 |
EP4146269A1 (en) * | 2020-05-04 | 2023-03-15 | Angarus Theraeutics, Inc. | Enpp1 inhibitors and methods of modulating immune response |
US11780849B2 (en) | 2020-05-04 | 2023-10-10 | Volastra Therapeutics, Inc. | Imino sulfanone inhibitors of ENPP1 |
WO2022125614A1 (en) * | 2020-12-09 | 2022-06-16 | Stingray Therapeutics, Inc. | Phosphonates as inhibitors of enpp1 and cdnp |
JP2024500249A (ja) * | 2020-12-09 | 2024-01-05 | スティングレイ・セラピューティクス・インコーポレイテッド | Enpp1およびcdnpの阻害剤としてのホスホネート類 |
WO2022199635A1 (zh) * | 2021-03-25 | 2022-09-29 | 南京明德新药研发有限公司 | 苄氨基喹唑啉类衍生物 |
CN115536696B (zh) * | 2021-06-29 | 2023-07-14 | 上海齐鲁制药研究中心有限公司 | Enpp1抑制剂 |
WO2023036289A1 (zh) * | 2021-09-10 | 2023-03-16 | 上海海和药物研究开发股份有限公司 | 具有enpp1抑制活性的异羟基肟酸类化合物及其用途 |
KR20230040756A (ko) | 2021-09-16 | 2023-03-23 | 삼성전자주식회사 | 위상 고정 루프의 모니터링 회로 및 이의 동작 방법 |
CA3235252A1 (en) | 2021-10-26 | 2023-05-04 | Duane GRANT | Magnetostrictive piezoelectric nanoassembly as cancer chemotherapeutic |
WO2023077083A1 (en) * | 2021-10-29 | 2023-05-04 | Angarus Therapeutics, Inc. | Enpp1 inhibitors as inhibitors of metastasis |
TW202329957A (zh) * | 2022-01-21 | 2023-08-01 | 大陸商上海海和藥物研究開發股份有限公司 | 膦酸類化合物及其前藥、它們的製備方法及用途 |
WO2023197987A1 (zh) * | 2022-04-11 | 2023-10-19 | 上海齐鲁制药研究中心有限公司 | Enpp1抑制剂 |
WO2024028727A1 (en) * | 2022-08-01 | 2024-02-08 | Sravathi Ai Technology Private Limited | Novel ectonucleotide pyrophosphatase / phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5136469A (ja) * | 1974-07-25 | 1976-03-27 | Pfizer | |
WO2003000188A2 (en) * | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
WO2008113161A1 (en) * | 2007-03-19 | 2008-09-25 | Ulysses Pharmaceutical Products Inc. | Phosphate prodrugs of quinazolinyl nitrofurans, methods of obtaining, and use of same |
JP2009242240A (ja) * | 2006-08-04 | 2009-10-22 | Mebiopharm Co Ltd | 含ホウ素キナゾリン誘導体 |
JP2010505955A (ja) * | 2006-10-10 | 2010-02-25 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 脂肪酸アミドヒドロラーゼのインヒビター |
JP2013523894A (ja) * | 2010-04-14 | 2013-06-17 | ブリストル−マイヤーズ スクイブ カンパニー | 新規グルコキナーゼアクチベーターおよびその使用方法 |
WO2013096680A1 (en) * | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
WO2017147328A1 (en) * | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
JP2017530193A (ja) * | 2014-09-22 | 2017-10-12 | ユ−シェン チャオ | 複素環式化合物及びその使用 |
JP2018513150A (ja) * | 2015-04-07 | 2018-05-24 | グアンドン・チョンシェン・ファーマスーティカル・カンパニー・リミテッド | チロシンキナーゼ阻害剤およびそれを含む医薬組成物 |
WO2018229139A1 (en) * | 2017-06-14 | 2018-12-20 | Fundación Para La Investigación Médica Aplicada | Novel compounds for use in cancer |
WO2019023635A1 (en) * | 2017-07-27 | 2019-01-31 | Stingray Therapeutics, Inc. | SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA228044A (en) | 1923-01-16 | Thomas Noble Boughton | Die for forming bolts | |
CA190896A (en) | 1919-02-24 | 1919-06-17 | Josephat C. Bergeron | Advertising device |
DE3319795A1 (de) * | 1983-06-01 | 1984-12-06 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von phosphonsaeureestern |
US10543207B2 (en) * | 2008-12-31 | 2020-01-28 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
AR083199A1 (es) * | 2010-09-29 | 2013-02-06 | Intervet Internationale B V | Compuestos de n-heteroarilo con unidad de puente ciclico |
US10011600B2 (en) * | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
US10518257B2 (en) * | 2017-05-04 | 2019-12-31 | Exxonmobil Research And Engineering Company | Metal organic frameworks, their synthesis and use |
-
2020
- 2020-01-30 SG SG11202108288YA patent/SG11202108288YA/en unknown
- 2020-01-30 PE PE2021001255A patent/PE20212306A1/es unknown
- 2020-01-30 MX MX2021009269A patent/MX2021009269A/es unknown
- 2020-01-30 JP JP2021544572A patent/JP2022523105A/ja active Pending
- 2020-01-30 MA MA054879A patent/MA54879A/fr unknown
- 2020-01-30 CN CN202080023701.0A patent/CN113677350A/zh active Pending
- 2020-01-30 WO PCT/US2020/015968 patent/WO2020160333A1/en unknown
- 2020-01-30 US US17/423,389 patent/US20220289775A1/en active Pending
- 2020-01-30 EP EP20749621.7A patent/EP3917536A4/en active Pending
- 2020-01-30 BR BR112021015098A patent/BR112021015098A2/pt unknown
- 2020-01-30 AU AU2020214628A patent/AU2020214628A1/en active Pending
- 2020-01-30 CA CA3128044A patent/CA3128044A1/en active Pending
- 2020-01-30 KR KR1020217025752A patent/KR20210124265A/ko unknown
- 2020-01-31 TW TW109103117A patent/TW202214571A/zh unknown
-
2021
- 2021-07-19 IL IL284961A patent/IL284961A/en unknown
- 2021-07-29 CL CL2021002002A patent/CL2021002002A1/es unknown
- 2021-07-30 CO CONC2021/0010186A patent/CO2021010186A2/es unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5136469A (ja) * | 1974-07-25 | 1976-03-27 | Pfizer | |
WO2003000188A2 (en) * | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
JP2009242240A (ja) * | 2006-08-04 | 2009-10-22 | Mebiopharm Co Ltd | 含ホウ素キナゾリン誘導体 |
JP2010505955A (ja) * | 2006-10-10 | 2010-02-25 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 脂肪酸アミドヒドロラーゼのインヒビター |
WO2008113161A1 (en) * | 2007-03-19 | 2008-09-25 | Ulysses Pharmaceutical Products Inc. | Phosphate prodrugs of quinazolinyl nitrofurans, methods of obtaining, and use of same |
JP2013523894A (ja) * | 2010-04-14 | 2013-06-17 | ブリストル−マイヤーズ スクイブ カンパニー | 新規グルコキナーゼアクチベーターおよびその使用方法 |
WO2013096680A1 (en) * | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
JP2017530193A (ja) * | 2014-09-22 | 2017-10-12 | ユ−シェン チャオ | 複素環式化合物及びその使用 |
JP2018513150A (ja) * | 2015-04-07 | 2018-05-24 | グアンドン・チョンシェン・ファーマスーティカル・カンパニー・リミテッド | チロシンキナーゼ阻害剤およびそれを含む医薬組成物 |
WO2017147328A1 (en) * | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
WO2018229139A1 (en) * | 2017-06-14 | 2018-12-20 | Fundación Para La Investigación Médica Aplicada | Novel compounds for use in cancer |
WO2019023635A1 (en) * | 2017-07-27 | 2019-01-31 | Stingray Therapeutics, Inc. | SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER |
Non-Patent Citations (5)
Title |
---|
BORA, SURANJANA ET AL.: "Synthesis and antimalarial activity evaluation of some isoquine analogues", MEDICINAL CHEMISTRY RESEARCH, vol. 20, no. 9, JPN6023053338, 2011, pages 1632 - 1637, XP019971273, ISSN: 0005228687, DOI: 10.1007/s00044-010-9460-9 * |
CHABRIER P. ET AL.: "Influence de la Phosphorylation sur les Proprietes Pharmacologiques des composes Biologiquement acti", ANNALES PHARMACEUTIQUES FRANCAISES, vol. 38, no. 1, JPN6023053335, 1980, pages 65 - 74, XP009011914, ISSN: 0005228690 * |
HIEU, D. T. ET AL.: "Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibit", CHEMISTRY & BIODIVERSITY, vol. 15, no. 6, JPN6023053339, 2018, pages 1 - 13, ISSN: 0005228686 * |
HIROI, KUNIO ET AL.: "New Chiral Sulfoxide Ligands Possessing a Phosphano or Phosphanoamino Functionality in Palladium-Cat", TETRAHEDRON, vol. 56, no. 27, JPN6023053337, 2000, pages 4701 - 4710, XP004206697, ISSN: 0005228688, DOI: 10.1016/S0040-4020(00)00393-8 * |
WANG, S. ET AL.: "Highly Efficient Synthesis of a Class of Novel Chiral-Bridged Atropisomeric Monophosphine Ligands vi", ORGANIC LETTERS, vol. 14, no. 8, JPN6023053336, 2012, pages 1966 - 1969, XP055971330, ISSN: 0005228689, DOI: 10.1021/ol300721p * |
Also Published As
Publication number | Publication date |
---|---|
BR112021015098A2 (pt) | 2022-01-11 |
WO2020160333A1 (en) | 2020-08-06 |
EP3917536A1 (en) | 2021-12-08 |
US20220289775A1 (en) | 2022-09-15 |
CL2021002002A1 (es) | 2022-03-11 |
CO2021010186A2 (es) | 2021-10-29 |
MA54879A (fr) | 2021-12-08 |
KR20210124265A (ko) | 2021-10-14 |
IL284961A (en) | 2021-09-30 |
MX2021009269A (es) | 2021-08-24 |
PE20212306A1 (es) | 2021-12-10 |
CN113677350A (zh) | 2021-11-19 |
SG11202108288YA (en) | 2021-08-30 |
AU2020214628A1 (en) | 2021-08-12 |
TW202214571A (zh) | 2022-04-16 |
CA3128044A1 (en) | 2020-08-06 |
EP3917536A4 (en) | 2022-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022523105A (ja) | 免疫応答をモジュレートするenpp1阻害剤および方法 | |
JP7292740B2 (ja) | Enpp1阻害剤及びがんの治療のためのそれらの使用 | |
AU2007321719B2 (en) | Inhibitors of kinase activity | |
KR20210098960A (ko) | Helios의 소분자 분해제 및 사용 방법 | |
CN112771053A (zh) | 基于生物标志物的治疗组合物 | |
AU2017273857A1 (en) | Compounds | |
EP3597186B1 (en) | Myc g-quadruplex stabilizing small molecules and their use | |
RU2641693C2 (ru) | Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение | |
TW201706272A (zh) | 雙環化合物 | |
RU2800798C2 (ru) | Ингибиторы ENPP1 и способы модуляции иммунного ответа | |
WO2018065607A1 (en) | Chemical substances which inhibit the enzymatic activity of human kallikrein related peptidase 6 (klk6) | |
WO2023035001A1 (en) | Enpp1 inhibitors and immune cells expressing chimeric antigen receptors | |
WO2024089008A1 (en) | Heterocyclic compounds capable of activating sting | |
CA3233398A1 (en) | Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221220 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221220 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231227 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240305 |